Growing out of the old self: management itself says the company has quietly become a different business, and the numbers
The model's full reasoning — Q4 2022 call → NOWe need to answer YES or NO based on the transcript. The question asks: does management convey that the company today is running on a different basis than its reported results and reputation were built on? That is, management describes the company as having crossed recently and substantially into being a different kind of business, while making clear that this change is not yet what the reported numbers or outside picture reflect. We need to look for management's own words describing a change of basis that is already real, and that the reported results/perception lag that change. Let's scan the transcript. Key points: Len Schleifer talks about strategic imperatives: fortify retinal franchise with aflibercept 8 mg, maintain Dupixent, become leader in immuno-oncology. He mentions "2022 turned out to be a crucial year" for oncology, with acquiring Sanofi's share of Libtayo. He says "we expect 2023 to be another notable year with significant incremental progress across these imperatives." He talks about "We are preparing for a potential U.S. launch for aflibercept 8 milligrams in late August" and "we believe that over time there is an opportunity for aflibercept 8 milligrams to become the new standard of care." That is future. Also Dupixent, COPD readout in first half of this year. Then he says "we also plan to rapidly move forward with clinical development of our next-generation COVID-19 antibody" - not yet. George Yancopoulos talks about pipeline progress. He mentions "in 2022, we presented pivotal positive results for aflibercept 8 mg" - that's data, but not yet approved. He talks about Dupixent approvals in 2022. Oncology: Libtayo approved in combination with chemo, "Libtayo is also emerging as an essential backbone of our oncology pipeline as several programs in combination with Libtayo are starting to yield encouraging data." He mentions fianlimab data, PSMAxCD28 early data. But these are early. Bob Landry talks about financial results. He says "Regeneron ended 2022 with a strong fourth quarter with continued execution driving positive results across the business. Excluding contributions from REGEN-COV and Ronapreve, fourth quarter total revenues increased 14% year-over-year to $3 billion, driven by growth across our core brands." That's about the reported results. He gives guidance for 2023.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
CALX · Q1 2023 → YESThe question is whether management conveys that the company today is running on a different basis than what its reported results and reputation were built on. Both parts: a change of basis already rea...YES The transcript shows management describing the company as now operating on a fundamentally different basis—selling into a new market of broadband service providers building consolidated networks, shifting from a legacy cyclical model to sequential revenue through platforms, clouds, and managed services—while treating this as an accomplished reality today, not a future plan. They emphasize numbers like 988 BSP deployments, 865 cloud customers, and 334 managed services customers, along with three years of over 25% growth, as evidence of this new foundation already in place.
SANG · Q2 2024 → YESThe question is whether management conveys that the company today is running on a different basis than the one its reported results and reputation were built on. Both parts: a real change of basis alr...
WD · Q2 2022 → YESThe question is whether management conveys that the company today is running on a different basis than the company its reported results and reputation were built on. Specifically, two parts: a change ...